WO2001089564A3 - Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity - Google Patents

Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity Download PDF

Info

Publication number
WO2001089564A3
WO2001089564A3 PCT/US2001/016021 US0116021W WO0189564A3 WO 2001089564 A3 WO2001089564 A3 WO 2001089564A3 US 0116021 W US0116021 W US 0116021W WO 0189564 A3 WO0189564 A3 WO 0189564A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
disorders
present
hemostatic
diagnosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/016021
Other languages
French (fr)
Other versions
WO2001089564A2 (en
Inventor
Denisa D Wagner
Patrick Andre
Daqing W Hartwell
Ingrid Hrachovinova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Immune Disease Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Disease Institute Inc filed Critical Immune Disease Institute Inc
Priority to EP01935660A priority Critical patent/EP1289552B1/en
Priority to AU2001261735A priority patent/AU2001261735B2/en
Priority to DE60118362T priority patent/DE60118362T2/en
Priority to JP2001585806A priority patent/JP2003534291A/en
Priority to CA002408883A priority patent/CA2408883A1/en
Priority to AU6173501A priority patent/AU6173501A/en
Publication of WO2001089564A2 publication Critical patent/WO2001089564A2/en
Publication of WO2001089564A3 publication Critical patent/WO2001089564A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention identifies P-selectin as a modulator of hemostasis. Accordingly, the present invention relates to methods for the identification and use of modulators of P-selectin activity as modulators of hemostasis. The invention also relates to methods and compositions for the diagnosis and treatment of hemostatic disorders, including, but not limited to, hemorrhagic disorders and thrombotic disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hemostatic conditions, and for the identification of subjects exhibiting a predisposition to such conditions. In addition, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of hemostatic or vascular disorders, and for monitoring the efficacy of compounds in clinical trials.
PCT/US2001/016021 2000-05-19 2001-05-17 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity Ceased WO2001089564A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP01935660A EP1289552B1 (en) 2000-05-19 2001-05-17 Methods for treating hemostatic disorders by soluble p-selectin
AU2001261735A AU2001261735B2 (en) 2000-05-19 2001-05-17 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
DE60118362T DE60118362T2 (en) 2000-05-19 2001-05-17 METHOD FOR TREATING HEMOSTATIC INTERFERENCE BY SOLUBLE P-SELECTIN
JP2001585806A JP2003534291A (en) 2000-05-19 2001-05-17 Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity
CA002408883A CA2408883A1 (en) 2000-05-19 2001-05-17 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
AU6173501A AU6173501A (en) 2000-05-19 2001-05-17 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20573400P 2000-05-19 2000-05-19
US60/205,734 2000-05-19

Publications (2)

Publication Number Publication Date
WO2001089564A2 WO2001089564A2 (en) 2001-11-29
WO2001089564A3 true WO2001089564A3 (en) 2002-05-10

Family

ID=22763420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016021 Ceased WO2001089564A2 (en) 2000-05-19 2001-05-17 Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity

Country Status (8)

Country Link
US (4) US20020031508A1 (en)
EP (1) EP1289552B1 (en)
JP (1) JP2003534291A (en)
AT (1) ATE321570T1 (en)
AU (2) AU6173501A (en)
CA (1) CA2408883A1 (en)
DE (1) DE60118362T2 (en)
WO (1) WO2001089564A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44778E1 (en) 2005-09-02 2014-02-25 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198639A1 (en) 2002-04-16 2003-10-23 Frenette Paul S. Methods of treating sickle cell disease
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
WO2003097658A2 (en) 2002-05-16 2003-11-27 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
JP2006502986A (en) * 2002-07-03 2006-01-26 グリコミメティクス， インコーポレイテッド Compositions and methods for diagnosis and treatment of medical conditions involved in angiogenesis
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
US8377887B1 (en) 2003-07-29 2013-02-19 Hsin-Hou Chang Methods of reducing hypoxic stress in a mammal by administering soluble P-selectin
TW200503734A (en) * 2003-07-29 2005-02-01 Hsin-Hou Chang New use of soluble p-selectin and anthrax lethal toxin
EP1763533B1 (en) * 2003-11-19 2008-01-09 GlycoMimetics, Inc. Specific antagonist for both e- and p-selectins
WO2005054264A2 (en) * 2003-11-19 2005-06-16 Glycomimetics, Inc. Glycomimetic antagonists for both e- and p-selectins
UY28886A1 (en) 2004-05-10 2005-12-30 Boehringer Ingelheim Int ANTIBODIES CONSISTING IN POLYPEPTIDES AND DERIVATIVES UNDERSTANDING THREE SEQUENCES CONCERNING THE FOLLOWING NUMBERS OF SEQ. ID: 1-3 AND 4-6; 7-9 AND 10-12 AND 13-15 OR 16-18
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
US7807636B1 (en) * 2004-11-12 2010-10-05 Wisconsin Alumni Research Foundation Bovine P-selectin glycorpotein ligand-1
US20090036386A1 (en) * 2005-05-25 2009-02-05 Glycomimetics, Inc Heterobifunctional compounds for selectin inhibition
CN101291946B (en) * 2005-08-09 2011-06-29 糖模拟物有限公司 Glycomimetic inhibitors of PA-IL lectin, PA-IIL lectin, or both from Pseudomonas
US20090176717A1 (en) * 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
EP3461499A1 (en) * 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
EP2074132B1 (en) 2006-10-12 2013-05-15 GlycoMimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
US20100104502A1 (en) * 2006-11-06 2010-04-29 The Regents Of The University Of Michigan Compositions and methods for detecting and treating endothelial dysfunction
HUE041957T2 (en) 2006-12-01 2019-06-28 Novartis Ag Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
AU2008216794A1 (en) * 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and N-acetyl hexosamines
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
RU2366366C1 (en) * 2007-12-14 2009-09-10 Государственное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО АГМУ Росздрава) Estimation method of haemostatic therapy effectiveness in tooth extraction in patients with haemorragic diseases
MX2010011145A (en) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Human serum albumin linkers and conjugates thereof.
US7833530B2 (en) * 2008-05-15 2010-11-16 Selexys Pharmaceuticals Corporation Methods of inhibiting the PSGL-1-mediated adhesion and chemokine-mediated migration with PSGL-1-specific antibodies
CN102088983B (en) * 2008-06-13 2013-01-30 糖模拟物有限公司 Treatment of cancers of the blood using selected glycomimetic compounds
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CA2760292A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
RU2428119C1 (en) * 2010-04-05 2011-09-10 Игорь Леонидович Давыдкин Method of diagnosing phases of inflammatory process in knee and ankle joints in patients with hemophilia
LT2555789T (en) * 2010-04-08 2020-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) INHIBITING PEPTIDES DERIVED FROM TREM TYPE TRANSCRIPT 1 (TLT-1) AND THEIR USE
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
EP3084437B1 (en) * 2013-12-18 2018-02-28 Siemens Healthcare Diagnostics Inc. Detection of endothelial disease
JP6689854B2 (en) 2014-12-03 2020-04-28 グリコミメティクス， インコーポレイテッド Heterobifunctional inhibitors of E-selectin and CXCR4 chemokine receptors
JP2019502727A (en) 2016-01-22 2019-01-31 グリコミメティクス， インコーポレイテッド PA-IL and / or PA-IIL lectin glycomimetic inhibitors
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
AU2017341065B2 (en) 2016-10-07 2023-04-06 Crescent Biopharma, Inc. Highly potent multimeric E-selectin antagonists
US20200087403A1 (en) * 2017-03-15 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of thrombosis in patients suffering from a myeloproliferative neoplasm
EP3596096A1 (en) 2017-03-15 2020-01-22 GlycoMimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
JP7275131B2 (en) 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド Methods of mobilizing bone marrow-infiltrating lymphocytes and uses thereof
KR20200104889A (en) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-selectin and heterobifunctional inhibitors of galectin-3
EP3758715B1 (en) * 2018-03-02 2025-12-03 Peter Gillies Agents inhibiting p-selectin expression and/or activity for use for inhibiting epithelial cell proliferation in the treatment of primary cancer
KR20200128025A (en) 2018-03-05 2020-11-11 글리코미메틱스, 인크. Methods of treatment of acute myeloid leukemia and related conditions
US20190388548A1 (en) * 2018-06-26 2019-12-26 Tzu Chi University Method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death
US20220403036A1 (en) * 2021-06-17 2022-12-22 The John's Hopkins University P-selectin inhibitor, compositions thereof and methods of use thereof
WO2023133555A2 (en) * 2022-01-10 2023-07-13 Zilker Sciences Llc Palmitoylethanolamide treatment for covid-19-related inflammation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012994A1 (en) * 1991-01-24 1992-08-06 Bristol-Myers Squibb Company Mixed specificity fusion proteins
WO1994011498A1 (en) * 1992-11-16 1994-05-26 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for p-selectin and methods of use thereof
WO1995006118A1 (en) * 1993-08-20 1995-03-02 Board Of Regents Of The University Of Oklahoma Expression control sequences of the p-selectin gene

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5026537A (en) * 1989-04-06 1991-06-25 Centocor, Inc. Methods for imaging atherosclerotic plaque
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
EP0606391B1 (en) 1991-09-30 1998-08-05 Biogen, Inc. Inhibition of vascular narrowing using anti-padgem antibodies
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US5483707A (en) * 1993-03-01 1996-01-16 Meyer; Douglas S. Self standing support structure and method
DE69533921T2 (en) * 1994-03-23 2005-12-01 Alexion Pharmaceuticals, Inc., New Haven METHOD FOR REDUCING MALFUNCTIONS OF IMMUNE SYSTEM AND HEMOSTASE DURING EXTRACORPOREAL CIRCULATION
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5510102A (en) * 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
US20020040008A1 (en) * 1995-01-24 2002-04-04 Wagner Denisa D. Method for treating and preventing atherosclerosis
US5763201A (en) * 1996-02-05 1998-06-09 Emory University Flow cytometry assay for heparin-induced thrombocytopenia
CA2247115C (en) * 1996-03-01 2008-11-18 The Regents Of The University Of California Inhibition of selectin binding
US6230713B1 (en) * 1998-01-29 2001-05-15 Margaret R. Dalesandro Determining a treatment plan for patients undergoing thrombotic event by monitoring P-selectin
US6596705B1 (en) * 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
US6391568B1 (en) * 1998-07-15 2002-05-21 Lionheart Technologies, Inc. Method for determining platelet reactivity in a whole blood sample
NZ511034A (en) * 1998-09-21 2004-03-26 American Nat Red Cross Methods of downmodulating the immune response to therapeutic proteins
US6277675B1 (en) * 1999-10-28 2001-08-21 United Microelectronics Corp. Method of fabricating high voltage MOS device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012994A1 (en) * 1991-01-24 1992-08-06 Bristol-Myers Squibb Company Mixed specificity fusion proteins
WO1994011498A1 (en) * 1992-11-16 1994-05-26 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for p-selectin and methods of use thereof
WO1995006118A1 (en) * 1993-08-20 1995-03-02 Board Of Regents Of The University Of Oklahoma Expression control sequences of the p-selectin gene

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A. SEMENOV ET AL.: "Soluble P-selectin - a marker of platelet activation and vessel wall injury. Increase of soluble P-selectin in the blood plasma of patients with myocardial infarction, massive atherosclerosis and primary pulmonary hypertension.", TERAPEVTICHESKII ARKHIV, vol. 72, no. 4, 2000, Russia, pages 15 - 20, XP001064077 *
E. PEERSCHKE ET AL.: "Platelet activation by C1q results in the induction of alpha-IIb/beta3 integrins (GPIIb/IIIa) and the expression of P-selectin and procoagulant activity.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 178, no. 2, August 1993 (1993-08-01), New York, NY, USA, pages 579 - 587, XP000655063 *
H. ZHANG ET AL.: "A recombinant soluble P-selectin glycoprotein ligand-1 chimera has a thrombolytic effect in a rat model of thrombosis.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 35, no. 2 suppl. A, February 2000 (2000-02-01), USA, pages 280A, XP001034262 *
J. STONE ET AL.: "P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer.", JOURNAL OF CLINICAL INVESTIGATION, vol. 82, August 1993 (1993-08-01), New York, NY, USA, pages 804 - 813, XP002927157 *
M. SHIMURA ET AL.: "Increased plasma soluble-adhesion molecules in thrombotic thrombocyopenic purpura and disseminated intravascular coagulation.", CLINICAL AND APPLIED THROMBOSIS/HEMOSTASIS, vol. 4, no. 3, 1998, New York, NY, USA, pages 196 - 200, XP001064068 *
M. SUBRAMANIAM ET AL.: "Defects in hemostasis in P-selectin-deficient mice.", BLOOD, vol. 87, no. 4, 15 February 1996 (1996-02-15), Philadelphia, PA, USA, pages 1238 - 1242, XP001064070 *
P. ANDRÉ ET AL.: "Pro-coagulant state resulting from high levels of soluble P-selectin in blood.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 97, no. 25, 5 December 2000 (2000-12-05), Washington, DC, USA, pages 13835 - 13840, XP002191822 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44778E1 (en) 2005-09-02 2014-02-25 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US9534009B2 (en) 2008-04-08 2017-01-03 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Also Published As

Publication number Publication date
JP2003534291A (en) 2003-11-18
US20020031508A1 (en) 2002-03-14
EP1289552A2 (en) 2003-03-12
EP1289552B1 (en) 2006-03-29
AU6173501A (en) 2001-12-03
DE60118362T2 (en) 2007-05-24
US20050202007A1 (en) 2005-09-15
US7387777B2 (en) 2008-06-17
US20080193949A1 (en) 2008-08-14
US20040265311A1 (en) 2004-12-30
AU2001261735B2 (en) 2006-09-21
ATE321570T1 (en) 2006-04-15
WO2001089564A2 (en) 2001-11-29
CA2408883A1 (en) 2001-11-29
DE60118362D1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
WO2001089564A3 (en) Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
WO2000035473A3 (en) Methods for detection and use of differentially expressed genes in disease states
Winn et al. The long‐term prognosis in untreated cerebral aneurysms: I. The incidence of late hemorrhage in cerebral aneurysm: A 10‐year evaluation of 364 patients
WO2005028029A3 (en) Patient monitoring, diagnosis, and/or therapy systems and methods
ATE440536T1 (en) METHODS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF BONE LOSS
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
Ruddy et al. Management of epistaxis in children
DE60122673D1 (en) METHODS OF DIAGNOSIS AND TREATMENT OF HEART DISEASES
Parslew et al. Localized unilateral hyperhidrosis secondary to an eccrine naevus.
ATE136940T1 (en) DIAGNOSTIC METHOD
WO2003061573A3 (en) Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
Sabate et al. Thromboelastography and blood product usage in cirrhosis with severe coagulopathy
WO2004071411A3 (en) Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620
ATE240352T1 (en) COMPLEX COMPOUNDS FOR THE DIAGNOSIS OF VASCULAR DISEASES
ATE390435T1 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES, INSULIN RESISTANCE AND DYSLIPIDEMIA
EP1240901A4 (en) Medicinal compositions for treating and preventing diseases based on abnormal blood coagulation
WO2003053364A3 (en) Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
AU2001261674A1 (en) Treatment methods using 17906 and uses therefor
WO2002058323A3 (en) Method for identifying modulators of bace
WO2004080535A3 (en) Methods and compositions for treating aids and hiv-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, or 46777
WO2003047421A3 (en) Methods and reagents for diagnosis and treatment of diabetes
WO2003039342A3 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
WO2003039476A3 (en) Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
AU5857899A (en) Use of tgf-beta inhibitors for treating cerebral disorders
WO2002095418A3 (en) Method of examining and diagnosing skin health

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2408883

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001935660

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001261735

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001935660

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001935660

Country of ref document: EP